- Home
- ABNB vs REGN Comparison
ABNB vs REGN Comparison
Compare ABNB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABNB | REGN |
|---|---|---|
| Founded | 2008 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8B | 68.8B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ABNB | REGN |
|---|---|---|
| Price | $149.92 | $760.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 25 |
| Target Price | $151.93 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 3.2M | 766.5K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 18.95 |
| Revenue | ★ $12,241,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $14.25 | $12.45 |
| Revenue Next Year | $10.05 | $10.13 |
| P/E Ratio | ★ $30.80 | $40.07 |
| Revenue Growth | 10.26 | ★ 20.82 |
| 52 Week Low | $110.81 | $541.00 |
| 52 Week High | $156.50 | $821.11 |
Technical Indicators
Market Signals| Indicator | ABNB | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 76.69 |
| Support Level | $134.67 | $738.17 |
| Resistance Level | N/A | $783.87 |
| Average True Range (ATR) | 3.59 | 20.43 |
| MACD | 0.27 | 10.29 |
| Stochastic Oscillator | 63.31 | 91.31 |
Price Performance
Historical ComparisonAbout ABNB Airbnb Inc.
Airbnb is the world's largest online alternative accommodation travel agency; it also offers booking services for boutique hotels, experiences, and hotel-like services. Airbnb's platform offers over 9 million active accommodation listings. Listings from the company's 5 million-plus hosts are spread over almost every country in the world. In 2025, 42% of revenue was from North America, 39% from Europe, the Middle East, and Africa, 10% from Latin America, and 9% from Asia-Pacific. Transaction fees for online bookings account for all its revenue.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.